CN114225041A - 一种非对称结构纳米材料及其制备方法及其应用 - Google Patents
一种非对称结构纳米材料及其制备方法及其应用 Download PDFInfo
- Publication number
- CN114225041A CN114225041A CN202111307505.9A CN202111307505A CN114225041A CN 114225041 A CN114225041 A CN 114225041A CN 202111307505 A CN202111307505 A CN 202111307505A CN 114225041 A CN114225041 A CN 114225041A
- Authority
- CN
- China
- Prior art keywords
- nanoparticle
- nano material
- nano
- asymmetric
- asymmetric structure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002086 nanomaterial Substances 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title abstract description 10
- 239000002105 nanoparticle Substances 0.000 claims abstract description 41
- 239000003814 drug Substances 0.000 claims abstract description 34
- 229940079593 drug Drugs 0.000 claims abstract description 27
- 208000014674 injury Diseases 0.000 claims abstract description 18
- 230000003197 catalytic effect Effects 0.000 claims abstract description 17
- 239000011248 coating agent Substances 0.000 claims abstract description 16
- 238000000576 coating method Methods 0.000 claims abstract description 16
- 229910052751 metal Inorganic materials 0.000 claims abstract description 14
- 239000002184 metal Substances 0.000 claims abstract description 14
- 230000014759 maintenance of location Effects 0.000 claims abstract description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 239000002077 nanosphere Substances 0.000 claims description 10
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 8
- 229910052710 silicon Inorganic materials 0.000 claims description 8
- 239000010703 silicon Substances 0.000 claims description 8
- 230000008736 traumatic injury Effects 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 238000004544 sputter deposition Methods 0.000 claims description 6
- 230000035699 permeability Effects 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 239000002356 single layer Substances 0.000 claims description 4
- 238000001755 magnetron sputter deposition Methods 0.000 claims description 3
- 229910000510 noble metal Inorganic materials 0.000 claims description 3
- 229910052723 transition metal Inorganic materials 0.000 claims description 3
- 150000003624 transition metals Chemical class 0.000 claims description 3
- 239000004793 Polystyrene Substances 0.000 claims description 2
- 239000000956 alloy Substances 0.000 claims description 2
- 229910045601 alloy Inorganic materials 0.000 claims description 2
- 238000007796 conventional method Methods 0.000 claims description 2
- 239000011258 core-shell material Substances 0.000 claims description 2
- 239000008204 material by function Substances 0.000 claims description 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 2
- 229920001690 polydopamine Polymers 0.000 claims description 2
- 239000004626 polylactic acid Substances 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000004408 titanium dioxide Substances 0.000 claims description 2
- 239000011787 zinc oxide Substances 0.000 claims description 2
- -1 hollow Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims 1
- 230000035515 penetration Effects 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 6
- 230000008733 trauma Effects 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 239000012620 biological material Substances 0.000 abstract description 2
- 238000013461 design Methods 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 238000011068 loading method Methods 0.000 abstract description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 description 20
- 230000009529 traumatic brain injury Effects 0.000 description 18
- 208000027418 Wounds and injury Diseases 0.000 description 16
- 238000012360 testing method Methods 0.000 description 12
- 206010052428 Wound Diseases 0.000 description 11
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 238000009792 diffusion process Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000033001 locomotion Effects 0.000 description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 210000005013 brain tissue Anatomy 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229940121657 clinical drug Drugs 0.000 description 3
- 210000001951 dura mater Anatomy 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010023204 Joint dislocation Diseases 0.000 description 2
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 208000006735 Periostitis Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001027 hydrothermal synthesis Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 229910052750 molybdenum Inorganic materials 0.000 description 2
- 239000011733 molybdenum Substances 0.000 description 2
- 230000007659 motor function Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 238000012634 optical imaging Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000001936 parietal effect Effects 0.000 description 2
- 210000003460 periosteum Anatomy 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 208000018680 Abdominal injury Diseases 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 208000007356 Fracture Dislocation Diseases 0.000 description 1
- 208000011092 Hand injury Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000029224 Thoracic injury Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000000806 cranial fontanelle Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000011807 nanoball Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007903 penetration ability Effects 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Nanotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Physics & Mathematics (AREA)
- Manufacturing & Machinery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属纳米生物新材料技术领域,具体涉及一种非对称结构纳米材料及其制备方法及其应用,包括无催化活性的纳米颗粒核、金属镀层;所述金属镀层仅分布在在所述无催化活性的纳米颗粒核一侧。其有益效果在于:提供了一种增强药物渗透和保留的新思路;同时提供了一种可用于外伤治疗的非对称结构纳米材料;模块化的设计可以将这自驱动平台轻易改造成可负载各种临床药物的递送载体,协助药物到达深层组织发挥作用,提高药物治疗效果;制备方法简单。
Description
技术领域
本发明属纳米生物新材料技术领域,涉及一种非对称结构纳米材料及其制备方法及其应用。
背景技术
创伤性损伤是机械因素引起的人体组织或器官破坏,常见于战争、自然灾害、交通事故、高空跌落、体育运动等,其发病突然,无法提前预防,严重威胁人类的生命健康。按受伤部位分类,创伤可分为颅脑创伤、胸部创伤、腹部创伤、各部位的骨折和关节脱位、手部伤等。根据病理过程,创伤通常可分为两个不同的阶段:原发性损伤和次级损伤。次级损伤是患者在医院死亡的主要原因。创伤发生几分钟后,损伤灶部位组织就会产生大量的自由基,不仅破坏核酸,蛋白质,脂质等生物分子结构,而且激活免疫细胞,进一步产生炎症因子风暴,最终导致不可逆的级联损伤。因此,寻找有效的自由基清除药物,清除产生的大量自由基,从而减少创伤后的次级损伤,这对于创伤治疗具有重要意义。
基于创伤常发生于野外以及需要快速施救的要求,局部给药,例如涂抹,喷洒,贴片或微针等方式,显示出巨大优势。这对于非医务救援者来说没有技术门槛。然而,由于组织具有细胞外基质孔隙小,细胞间隙压力大等特点,局部给药常面临药物渗透深度不足,扩散慢的困难。而且,很多药物半衰期短,代谢清除较快,这都严重限制了药物疗效。
因此,本发明提供了一种具有自驱动能力的药物,其在伤口位置产生剧烈氧化应激的情况下,可分解活性氧产生氧气气泡,不仅能够减少氧化应激引起的次级损伤,而且能够产生驱动力提高药物渗透能力及保留时间。本发明提供的纳米药物不仅本身具有改善次级损伤的作用,而且能够轻易改造成负载临床药物的递送平台,在外伤治疗领域具有极大的临床转化潜力。
发明内容
本发明所要解决的技术问题在于克服局部治疗中药物渗透能力差,保留时间短等缺陷,提供了一种提高药物渗透和保留的方法和平台,为创伤性损伤治疗提供了新的思路和手段。本发明提供的非对称结构纳米材料的自推进无需外部设备的辅助,其本身可以高效分解伤口组织产生的大量毒性自由基,既减轻氧化应激损伤,又产生气泡造成纳米颗粒两侧不对称压力,从而驱动纳米药物自推进,显著提高其渗透深度。而且,药物的自推进延长了其在组织中的保留时间。本发明提供的非对称结构纳米材料其特征在于既可以作为抗炎、抗氧化的有效成分之一,亦可以作为药物载体平台,负载各种临床药物,增强药物的渗透能力,从而提高治疗效果。
本发明公开了一种非对称结构纳米材料,包括无催化活性的纳米颗粒核、金属镀层;所述金属镀层仅分布在在所述无催化活性的纳米颗粒核一侧。
进一步地,所述无催化活性的纳米颗粒为碳纳米球、聚苯乙烯纳米粒子、聚多巴胺纳米粒子、聚乳酸纳米粒子、聚ε-己内酯纳米粒子、聚乳酸-羟基乙酸纳米粒子、二氧化硅纳米粒子、二氧化钛纳米颗粒、氧化锌纳米颗粒中的一种。
进一步地,所述无催化活性的纳米颗粒的粒径为50-1000nm。
优选地,所述无催化活性的纳米颗粒的粒径为80-200nm。
进一步地,所述无催化活性的纳米颗粒为实心、空心、核壳以及介孔结构中的任意一种。
进一步地,无催化活性的纳米颗粒采用所述空心或介孔结构时,所述无催化活性的纳米颗粒负载功能材料。
优选地,所述功能材料采用天然药物、半合成药物、合成药物、基因工程药物中的一种或多种。
进一步地,所述金属镀层采用至少一种贵金属与至少一种过渡金属形成的合金,元素分布均匀。
优选地,所述贵金属采用钌、铑、钯、锇、铱、铂、金、银中至少一种;所述过渡金属采用钒、铁、钴、镍、铜、锌、钼中至少一种。
本发明还公开了一种非对称结构纳米材料的制备方法,包括如下步骤:
步骤1,利用常规方法制备无催化活性的纳米颗粒;
步骤2,将步骤1制备的所述无催化活性的纳米颗粒均匀分布在硅片上;并通过磁控溅射镀膜仪共溅射形成金属镀层;即为非对称结构纳米材料;
步骤3,将步骤2制备的所述非对称结构纳米材料从硅片上剥离并重悬,保存。
进一步地,所述步骤2中,所述无催化性质的纳米颗粒呈单层分布。
进一步地,所述步骤2中,所述共溅射镀膜溅射时间为1-3min。
进一步的,所述步骤3中,所述非对称结构纳米材料从硅片上剥离的方法采用高强度超声处理。
优选地,所述超声处理步骤中,超声功率为300-1000W,超声时间为0.5-24h。
本发明还公开了非对称结构纳米材料用于制备的创伤性外伤药物的应用。
进一步地,所述创伤性外伤包括颅脑创伤、胸部创伤、腹部创伤、各部位的骨折和关节脱位、手部伤。
进一步地,非对称结构纳米材料用于制备的创伤性外伤药物时,使用浓度为0.1-5000μg/mL。
进一步地,非对称结构纳米材料用于制备的创伤性外伤药物时,使用方式为喷洒、涂抹、贴片、微针、局部注射中至少一种。
进一步地,非对称结构纳米材料用于制备的创伤性外伤药物时,使用时间为损伤后0-6h。
本发明还公开了非对称结构纳米材料用于提高药物渗透能力载体的应用。
本发明还公开了非对称结构纳米材料用于提高药物保留时间载体的应用。
本发明的有益效果在于:
1、提供了一种增强药物渗透和保留的新思路;同时提供了一种可用于外伤治疗的非对称结构纳米材料;
2、模块化的设计可以将这自驱动平台轻易改造成可负载各种临床药物的递送载体,协助药物到达深层组织发挥作用,提高药物治疗效果。
3、制备方法简单。
附图说明
图1为实施例1中碳纳米球的扫描电镜图;
图2为非对称结构纳米材料的透射电镜图;
图3为非对称结构纳米材料的过氧化氢分解能力测试;
图4为非对称结构纳米材料在过氧化氢水溶液中的表观扩散系数测试;
图5为非对称结构纳米材料在TBI模型鼠中渗透能力测试;
图6为非对称结构纳米材料在TBI模型鼠中保留能力测试;
图7为非对称结构纳米材料治疗TBI模型鼠的效果测试;
具体实施方式
下面结合实施例对本发明的具体实施方式作进一步描述,以下实施例仅用于更加清楚地说明本发明的技术实施例,而不能以此来限制本发明的保护范围。
实施例1(JCNs)
一种非对称结构纳米材料的制备方法,包括以下步骤:
S1:碳纳米球的制备:
首先将1.029g葡萄糖溶于20mL去离子水中,之后将其转移至25mL水热合成反应釜中,加热至180℃并维持3h。最后,通过离心和多次水洗去除未反应的葡萄糖,得到碳纳米球。
S2:多金属镀层的制备:
首先将上一步得到的碳纳米球分散于酒精中,滴加到硅片上得到单层分布的碳纳米球。将得到的碳纳米球进行扫描电镜分析。如图1所示,扫描电镜结果证明得到的碳纳米球呈规则的球形,粒径为106nm左右,呈单层分布于硅片上。
之后通过磁控溅射镀膜仪共溅射铂、钯、钼三种元素,溅射时间均为41s,溅射完成后通过高强度超声将非对称结构纳米材料从硅片上剥离下来,超声功率为840W,超声时间为6h,之后通过离心得到非对称结构纳米材料。通过透射电子显微镜观察制得的非对称结构纳米材料,如图2所示,其呈明显的非对称结构,金属镀层分布于碳纳米球的一侧。
实施例2(Pt-CNs)
与实施例1的区别在于其金属镀层仅有铂元素。
对比例1(CNs):
与实施例相比较,对比例1仅仅采用与实施例1相同无驱动能力的纳米颗粒,无金属镀层。其具体制备步骤如下:
首先将1.029g葡萄糖溶于20mL去离子水中,之后将其转移至25mL水热合成反应釜中,加热至180℃并维持3h。最后,通过离心和多次水洗去除未反应的葡萄糖,得到碳纳米球。
为了测试本发明的有益效果,特设置如下应用例1-4。
应用例1
非对称结构纳米材料的过氧化氢分解能力测试
将制备的非对称结构纳米材料重悬于PBS缓冲液中(pH7.4),配置成浓度为1mg/mL的分散液。取10μL加入1.5mL的3mM过氧化氢溶液中,1分钟后用数码相机拍照观察气泡产生的多少。从图3中可以看出,JCNs具有最多的气泡,证明其具有最高的催化效果。
应用例2
非对称结构纳米材料在过氧化氢溶液中的扩散能力测试
将制备的非对称结构纳米材料重悬于PBS缓冲液中(pH7.4),配置成浓度为1mg/mL的分散液。取10μL加入1mL的3mM过氧化氢溶液中,采用动态光散射仪(DLS)测试表观扩散系数。从图4中可以看出,JCNs具有最高的表观扩散系数,证明其在过氧化氢溶液中具有更好的扩散能力。
应用例3
非对称结构纳米材料在创伤性脑外伤模型鼠中的渗透能力测试
外伤性脑损伤(traumatic brain injury,TBI)是一种具有高致残率和致死率的创伤,因此选择TBI模型来验证非对称结构纳米材料的渗透能力。将制备的JCNs配置成浓度为1mg/mL的溶液,用于制备治疗TBI的药物。为了说明其能提高在TBI模型鼠中的渗透,特做出如下检测:
首先,TBI造模方法如下:C57BL6/J鼠(SPF级、雄性、8-10周龄、体重22±3g)购于联通利华动物有限公司。小鼠称重后腹腔注射麻醉,头部剪毛消毒,于头皮正中切开,切口长2cm,剥离左侧颅顶骨膜,固定于小鼠脑立体定位仪上,用颅骨钻磨一小孔,在前囟左侧2mm钻一直径4mm的骨窗,暴露硬脑膜并使其完整。应用自由落体法,使用40g砝码从3cm高处坠落,撞击于硬脑膜表面上的圆柱体。撞击硬脑膜的圆柱体直径为4mm,建立脑外伤模型,逐层消毒以预防创口感染,缝合头皮。此记为模型组(TBI)。对照组小鼠只做到钻骨窗(Sham)。在模型组的破溃处滴加10μL的1mg/mL的JCNs,此记为给药组(TBI+JCNs)。
具体检测指标如下:
为在组织内观察JCNs的分布,采用Cy5标记JCNs。给药4h后,用4%多聚甲醛溶液灌流,收取脑组织,并置于4%多聚甲醛溶液中浸泡过夜。之后将脑组织纵向切成厚度为1mm的脑片,小动物活体光学成像系统成像观察JCNs渗透深度,激发波长640nm,发射波长680nm。从图5中可以看出,相比无催化活性的CNs,自驱动的JCNs具有更大的扩散面积,因此证明其在脑组织内具有更高的扩散能力。
应用例4
非对称结构纳米材料在TBI模型鼠中的保留能力测试
为说明JCNs具有延长保留时间的效益,特做出如下检测:
为在TBI模型鼠体内观察JCNs的分布,采用Cy5标记JCNs。给药后,在6及24h通过小动物活体光学成像系统成像观察JCNs的保留时间,激发波长640nm,发射波长680nm。从图6中可以看出,相比无催化活性的CNs,自驱动的JCNs在TBI模型鼠脑组织内具有更长的保留时间。
应用例5
非对称结构纳米材料对TBI小鼠运动行为障碍的治疗作用评估
为了评估JCNs的治疗效果,采用转棒实验来测试TBI模型鼠运动功能。转棒是一种检测动物运动能力的方法,当神经系统疾病或者损害时会对动物的运动协调能力产生一定的影响,通过检测动物在滚筒上持续运动的时间判断动物的运动能力。小鼠转棒疲劳仪设置转速为300rpm/min,加速时间为300s。实验开始前3天,适应性训练使各组小鼠达到同一水平。造模给药24h后,检测小鼠从转棒仪掉落的时间。从图7中可以看出,相比Sham组,TBI组很短的时间便会掉落,证明其存在运动功能缺陷。而非对称结构纳米材料治疗组则明显延长了其在滚筒上运动的时间,证明其明显减轻了TBI模型鼠运动功能缺陷。
最后应说明的是:以上各实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述各实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分或者全部技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的范围。
Claims (10)
1.一种非对称结构纳米材料,其特征在于,包括无催化活性的纳米颗粒核、金属镀层;所述金属镀层仅分布在在所述无催化活性的纳米颗粒核一侧。
2.根据权利要求1所述的非对称结构纳米材料,其特征在于,所述无催化活性的纳米颗粒为碳纳米球、聚苯乙烯纳米粒子、聚多巴胺纳米粒子、聚乳酸纳米粒子、聚ε-己内酯纳米粒子、聚乳酸-羟基乙酸纳米粒子、二氧化硅纳米粒子、二氧化钛纳米颗粒、氧化锌纳米颗粒中的一种。
3.根据权利要求1所述的非对称结构纳米材料,其特征在于,所述无催化活性的纳米颗粒的粒径为50-1000nm。
4.根据权利要求1所述的非对称结构纳米材料,其特征在于,所述无催化活性的纳米颗粒为实心、空心、核壳以及介孔结构中的任意一种;无催化活性的纳米颗粒采用所述空心或介孔结构时,所述无催化活性的纳米颗粒负载功能材料。
5.根据权利要求1所述的非对称结构纳米材料,其特征在于,所述金属镀层采用至少一种贵金属与至少一种过渡金属形成的合金,元素分布均匀。
6.一种非对称结构纳米材料的制备方法,包括如下步骤:
步骤1,利用常规方法制备无催化活性的纳米颗粒;
步骤2,将步骤1制备的所述无催化活性的纳米颗粒均匀分布在硅片上;并通过磁控溅射镀膜仪共溅射形成金属镀层;即为非对称结构纳米材料;
步骤3,将步骤2制备的所述非对称结构纳米材料从硅片上剥离并重悬,保存。
7.根据权利要求6所述的非对称结构纳米材料的制备方法,其特征在于,所述步骤2中,所述无催化性质的纳米颗粒呈单层分布。
8.根据权利要求1-5任意一项所述的非对称结构纳米材料用于制备的创伤性外伤药物的应用。
9.根据权利要求1-5任意一项所述的非对称结构纳米材料用于提高药物渗透能力载体的应用。
10.根据权利要求1-5任意一项所述的非对称结构纳米材料用于提高药物保留时间载体的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111307505.9A CN114225041B (zh) | 2021-11-05 | 2021-11-05 | 一种非对称结构纳米材料及其制备方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111307505.9A CN114225041B (zh) | 2021-11-05 | 2021-11-05 | 一种非对称结构纳米材料及其制备方法及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114225041A true CN114225041A (zh) | 2022-03-25 |
CN114225041B CN114225041B (zh) | 2024-06-11 |
Family
ID=80748529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111307505.9A Active CN114225041B (zh) | 2021-11-05 | 2021-11-05 | 一种非对称结构纳米材料及其制备方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114225041B (zh) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010105864A (ja) * | 2008-10-30 | 2010-05-13 | National Institute Of Advanced Industrial Science & Technology | 過酸化水素の連続分解方法 |
US20120301720A1 (en) * | 2009-11-16 | 2012-11-29 | Basf Se | Metal island coatings and method for synthesis |
US20170175720A1 (en) * | 2015-12-16 | 2017-06-22 | The University Of Hong Kong | Nanomotor Propulsion |
WO2018030785A1 (ko) * | 2016-08-09 | 2018-02-15 | 한양대학교 에리카산학협력단 | 전기적 자극 반응성을 지닌 이중 금속-전도성 고분자 야누스 복합 나노구조체, 이의 콜로이드 자가 조립 구조체, 제조방법 및 바이오센싱, 바이오이미징, 약물전달 및 산업적 응용 |
US20190070314A1 (en) * | 2017-03-28 | 2019-03-07 | The Regents Of The University Of California | Nano/micromotors for active and dynamic intracellular payload delivery |
CN109999738A (zh) * | 2019-03-20 | 2019-07-12 | 华中科技大学 | 光磁双重响应的Janus粒子、制备和应用与形貌调控方法 |
CN110755383A (zh) * | 2019-10-16 | 2020-02-07 | 华南理工大学 | 一种自驱动二氧化锰纳米马达及其制备方法与应用 |
KR20210127515A (ko) * | 2020-04-14 | 2021-10-22 | 경희대학교 산학협력단 | 팔라듐-귀금속 코어-쉘 나노입자의 제조방법 및 과산화수소 제조용 촉매 |
US20220016223A1 (en) * | 2018-12-05 | 2022-01-20 | Fundació Institut De Bioenginyeria De Catalunya | Functionalized Enzyme-Powered Nanomotors |
-
2021
- 2021-11-05 CN CN202111307505.9A patent/CN114225041B/zh active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010105864A (ja) * | 2008-10-30 | 2010-05-13 | National Institute Of Advanced Industrial Science & Technology | 過酸化水素の連続分解方法 |
US20120301720A1 (en) * | 2009-11-16 | 2012-11-29 | Basf Se | Metal island coatings and method for synthesis |
US20170175720A1 (en) * | 2015-12-16 | 2017-06-22 | The University Of Hong Kong | Nanomotor Propulsion |
WO2018030785A1 (ko) * | 2016-08-09 | 2018-02-15 | 한양대학교 에리카산학협력단 | 전기적 자극 반응성을 지닌 이중 금속-전도성 고분자 야누스 복합 나노구조체, 이의 콜로이드 자가 조립 구조체, 제조방법 및 바이오센싱, 바이오이미징, 약물전달 및 산업적 응용 |
US20190070314A1 (en) * | 2017-03-28 | 2019-03-07 | The Regents Of The University Of California | Nano/micromotors for active and dynamic intracellular payload delivery |
US20220016223A1 (en) * | 2018-12-05 | 2022-01-20 | Fundació Institut De Bioenginyeria De Catalunya | Functionalized Enzyme-Powered Nanomotors |
CN109999738A (zh) * | 2019-03-20 | 2019-07-12 | 华中科技大学 | 光磁双重响应的Janus粒子、制备和应用与形貌调控方法 |
CN110755383A (zh) * | 2019-10-16 | 2020-02-07 | 华南理工大学 | 一种自驱动二氧化锰纳米马达及其制备方法与应用 |
KR20210127515A (ko) * | 2020-04-14 | 2021-10-22 | 경희대학교 산학협력단 | 팔라듐-귀금속 코어-쉘 나노입자의 제조방법 및 과산화수소 제조용 촉매 |
Non-Patent Citations (11)
Title |
---|
BERTA ESTEBAN-FERNÁNDEZ DE ÁVILA 等: "Micromotor-enabled active drug delivery for in vivo treatment of stomach infection", 《NATURE COMMUNICATIONS》 * |
BERTA ESTEBAN-FERNÁNDEZ DE ÁVILA 等: "Micromotor-enabled active drug delivery for in vivo treatment of stomach infection", 《NATURE COMMUNICATIONS》, vol. 8, 16 August 2017 (2017-08-16) * |
JIANAN SU 等: "The janus in monodispersed catalysts: synergetic interactions", 《JOURNAL OF MATERIALS CHEMISTRY A》 * |
JIANAN SU 等: "The janus in monodispersed catalysts: synergetic interactions", 《JOURNAL OF MATERIALS CHEMISTRY A》, 27 January 2021 (2021-01-27) * |
XING MA 等: "Catalytic Mesoporous Janus Nanomotors for Active Cargo Delivery", 《J. AM. CHEM. SOC.》, vol. 137, no. 15, pages 4977 * |
YI XING 等: "Core@Satellite Janus Nanomotors with pH-Responsive Multi-phoretic Propulsion", 《ANGEW. CHEM. INT. ED.》 * |
YI XING 等: "Core@Satellite Janus Nanomotors with pH-Responsive Multi-phoretic Propulsion", 《ANGEW. CHEM. INT. ED.》, vol. 59, 7 June 2020 (2020-06-07) * |
周婉蓉等: "Janus粒子的制备及功能化应用", 《化学进展》 * |
周婉蓉等: "Janus粒子的制备及功能化应用", 《化学进展》, no. 11, 24 November 2018 (2018-11-24) * |
张茂洁等: "气泡驱动型微马达功能材料可控制备研究新进展", 《中国科学:化学》 * |
张茂洁等: "气泡驱动型微马达功能材料可控制备研究新进展", 《中国科学:化学》, no. 06, 27 December 2018 (2018-12-27) * |
Also Published As
Publication number | Publication date |
---|---|
CN114225041B (zh) | 2024-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3285782B1 (en) | Methods of tissue repair and regeneration | |
JP2016516754A5 (zh) | ||
JP2008546842A (ja) | 酸化セリウムナノ粒子の抗炎症性、放射線防護性および寿命促進能 | |
KR20190010542A (ko) | 포유동물 조직 중의 산소량을 증가시키는 포접체를 포함하는 다중산소화된 금속 하이드록사이드 | |
Popova et al. | Fabrication of CeO2 nanoparticles embedded in polysaccharide hydrogel and their application in skin wound healing | |
CN113813383A (zh) | 一种过氧化铜透皮微针系统及其制备方法和应用 | |
JP2021512923A (ja) | 医薬組成物、組成物の添加剤及び組成物の使用 | |
Alavi et al. | Bioresponsive nanotechnology in pediatric dental drug delivery | |
CN114225041B (zh) | 一种非对称结构纳米材料及其制备方法及其应用 | |
CN115227671B (zh) | 一种药物递送系统及其制备方法和应用 | |
Sun et al. | Drug release from porous silicon for stable neural interface | |
CA3083357C (en) | Anisotropic nanoparticle compositions and methods | |
Karthikeyan et al. | Nanovaccination: Evolution and review | |
Jari et al. | Therapeutic effects of silver nanoparticles loaded with albendazole, mebendazole drugs in male albino mice infected with hydatid cysts | |
CN112089703B (zh) | 一种负载唑来膦酸的沸石咪唑框架纳米粒材料的制备方法 | |
US9649337B2 (en) | Cerium oxide nanoparticles for the treatment and prevention of stroke and cardiovascular disease | |
Kumarage et al. | Nanotechnology Applications in Biomaterials; A review | |
Abe et al. | In vivo internal diffusion of several inorganic microparticles through oral administration | |
Kulig et al. | Material engineering for atopic dermatitis treatment | |
TWI461203B (zh) | 腫瘤血管栓塞劑以及金奈米粒子之用途 | |
Sahu et al. | Novel Approaches of Treatment of Cancer: Nanoparticle | |
Christmann | Follicular targeted drug delivery via nanocarriers in the treatment of (auto) inflammatory skin diseases | |
Verma et al. | Environmental and Toxicological Implications of Nanopharmaceuticals: An Overview | |
Jain et al. | Miscellaneous applications | |
Dai et al. | Carbon dots-supported Zn single atom nanozymes for the catalytic therapy of diabetic wounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |